In the last trading session, 3.22 million Seelos Therapeutics Inc (NASDAQ:SEEL) shares changed hands as the company’s beta touched 2.07. With the company’s per share price at $0.13 changed hands at $0.01 or 1.36% during last session, the market valuation stood at $20.41M. SEEL’s last price was a discount, traded about -1176.92% off its 52-week high of $1.66. The share price had its 52-week low at $0.11, which suggests the last value was 15.38% up since then. When we look at Seelos Therapeutics Inc’s average trading volume, we note the 10-day average is 3.84 million shares, with the 3-month average coming to 5.29 million.
Analysts gave the Seelos Therapeutics Inc (SEEL) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SEEL as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Seelos Therapeutics Inc’s EPS for the current quarter is expected to be $Seelos Therapeutics, Inc..
Seelos Therapeutics Inc (NASDAQ:SEEL) trade information
Instantly SEEL was in green as seen at the end of in last trading. With action -12.82%, the performance over the past five days has been red. The jump to weekly highs of 0.1484 on Friday, 11/17/23 added 1.36% to the stock’s daily price. The company’s shares are showing year-to-date downside of -81.37%, with the 5-day performance at -12.82% in the red. However, in the 30-day time frame, Seelos Therapeutics Inc (NASDAQ:SEEL) is -32.32% down. Looking at the short shares, we see there were 8.32 million shares sold at short interest cover period of 1.95 days.
The consensus price target for the stock as assigned by Wall Street analysts is $4.00, meaning bulls need an upside of 96.75% from its current market value. According to analyst projections, SEEL’s forecast low is $4.00 with $4.00 as the target high. To hit the forecast high, the stock’s price needs a -2976.92% plunge from its current level, while the stock would need to soar -2976.92% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 53.03%. The 2023 estimates are for Seelos Therapeutics Inc earnings to increase by 51.28%.
Seelos Therapeutics Inc is expected to release its next quarterly earnings report on November 14.
Seelos Therapeutics Inc (NASDAQ:SEEL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.81% of Seelos Therapeutics Inc shares while 20.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 20.95%. There are 20.36% institutions holding the Seelos Therapeutics Inc stock share, with Gendell, Jeffrey L. the top institutional holder. As of Jun 29, 2023, the company held 4.04% of the shares, roughly 5.17 million SEEL shares worth $6.18 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 3.91% or 5.0 million shares worth $5.97 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 3.36 million shares estimated at $4.01 million under it, the former controlled 2.62% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.14% of the shares, roughly 1.46 million shares worth around $1.74 million.